High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.27B
+69.16%
5.819
+685.19%
1.36B
+70.53%
6.818
+167.16%
1.46B
+51.66%
7.431
+99.81%
Estimates Revision
The market is revising No Change the revenue expectations for argenx SE (ARGX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 24.85%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+24.85%
In Past 3 Month
21 Analyst Rating
Wall Street analysts forecast ARGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARGX is 956.06 USD with a low forecast of 780.00 USD and a high forecast of 1146 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Buy
1 Hold
0 Sell
Strong Buy
Current: 915.970
Low
780.00
Averages
956.06
High
1146
Current: 915.970
Low
780.00
Averages
956.06
High
1146
Wolfe Research
Andy Chen
Outperform -> Peer Perform
downgrade
2025-11-24
Reason
Wolfe Research
Andy Chen
Price Target
2025-11-24
downgrade
Outperform -> Peer Perform
Reason
Wolfe Research analyst Andy Chen downgraded Argenx to Peer Perform from Outperform without a price target. The stock's valuation is nearing a "ceiling" and the company's catalysts are "poorer" going forward, the analyst tells investors in a research note.
Citi
Buy
maintain
2025-11-17
Reason
Citi
Price Target
2025-11-17
maintain
Buy
Reason
Citi raised the firm's price target on Argenx to $1,124 from $1,041 and keeps a Buy rating on the shares. The firm left a meeting with management with more confidence in Argenx's commercial potential. Citi's U.S. neurologist survey points to continued expansion opportunities in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy for the company.
Wedbush
downgrade
2025-11-14
Reason
Wedbush
Price Target
2025-11-14
downgrade
Reason
Wedbush is removing Argenx from the firm's Best Ideas List. Wedbush remains constructive on the name, but believes the upside isn't compelling enough to warrant inclusion on the BIL.
JPMorgan
NULL -> Overweight
maintain
$830 -> $925
2025-11-07
Reason
JPMorgan
Price Target
$830 -> $925
2025-11-07
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Argenx to $925 from $830 and keeps an Overweight rating on the shares.
Piper Sandler
Overweight
maintain
$820 -> $930
2025-11-04
Reason
Piper Sandler
Price Target
$820 -> $930
2025-11-04
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Argenx to $930 from $820 and keeps an Overweight rating on the shares. The firm notes the company delivered a strong Q3 print, delivering over $1B of Vyvgart revenue in a quarter for the first time. Piper thinks the upcoming year provides multiple upside opportunities for Argenx shares through Vyvgart, with continued commercial growth and multiple expansion opportunities, not to mention opportunities from the assets in the pipeline. Argenx remains a top pick for 2025 and beyond, Piper says, adding that it remains a buyer.
Deutsche Bank
Hold
maintain
2025-11-03
Reason
Deutsche Bank
Price Target
2025-11-03
maintain
Hold
Reason
Deutsche Bank raised the firm's price target on Argenx to EUR 675 from EUR 655 and keeps a Hold rating on the shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for argenx SE (ARGX.O) is 32.22, compared to its 5-year average forward P/E of -72.27. For a more detailed relative valuation and DCF analysis to assess argenx SE 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-72.27
Current PE
32.22
Overvalued PE
141.36
Undervalued PE
-285.90
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-10.11
Current EV/EBITDA
28.78
Overvalued EV/EBITDA
92.97
Undervalued EV/EBITDA
-113.18
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
28.07
Current PS
10.27
Overvalued PS
49.98
Undervalued PS
6.17
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ARGX News & Events
Events Timeline
(ET)
2025-11-06
16:29:02
Denali's Chief Medical Officer Carole Ho to Leave for Eli Lilly
2025-11-05 (ET)
2025-11-05
09:55:33
Argenx Receives Health Canada Approval for Vyvgart in Treating CIDP
2025-10-30 (ET)
2025-10-30
06:15:50
Argenx Announces Q3 Earnings Per Share of $5.18, Exceeding Consensus Estimate of $3.56
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/c4827927ad7b710fe1ef666cd0a4b397268f9d1b949c2cb21aacc9c88f242d72.png)
Preview
4.0
11-24BenzingaArgenx Analyst Changes Stance; Check Out the Top 5 Downgrades for Monday
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/137f1946cea475ef5eef73d70650fbfdd3cde891be1c685a02e0959fdcf8489d.jpg)
Preview
4.0
11-24BenzingaWolfe Research Lowers Argenx Rating to Peer Perform
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/d782b5967702c1ec5325833403a21135d59b80341716415c669e7d3b43f8d675.png)
Preview
6.0
11-17BenzingaCitigroup Reaffirms Buy Rating on argenx and Increases Price Target to $1124
Sign Up For More News
People Also Watch
FAQ
What is argenx SE (ARGX) stock price today?
What is argenx SE (ARGX)'s business?
What is the price predicton of ARGX Stock?
What is argenx SE (ARGX)'s revenue for the last quarter?
What is argenx SE (ARGX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for argenx SE (ARGX)'s fundamentals?
How many employees does argenx SE (ARGX). have?